Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesMyelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
British Journal of Cancer, 10/26/09
Kumar R et al. – Activity against c–kit and Flt–3 by multikinase angiogenesis inhibitors provide a potential explanation for the differences in myelosuppression observed with these agents in patients.
Related Articles
Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations
Clinical Gastroenterology and Hepatology, 11/04/09
Relevance Score: 89%
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
Annals of Oncology, 11/17/09
Relevance Score: 80%
Thrombopoietin and thrombocytopenia in anorexia nervosa with severe liver dysfunction
International Journal of Eating Disorders, 10/09/09
Relevance Score: 80%
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Blood, 10/30/09
Relevance Score: 77%
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 77%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study)
Clinical and Translational Oncology, 11/25/09
Hemorrhagic Gastritis and Duodenitis Following Celiac Plexus Neurolysis
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor